Everolimus Tablet, For Suspension
FDA Label NDC 60219-2280

47 label sections · Submitted to the FDA by Amneal Pharmaceuticals Ny Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Ny Llc for the product Everolimus (NDC 60219-2280). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.5 tuberous sclerosis complex (tsc)-associated subependymal giant cell astrocytoma (sega), 1.6 tuberous sclerosis complex (tsc)-associated partial-onset seizures, 2.1 important dosage information, 2.6 recommended dosage for tuberous sclerosis complex (tsc)-associated subependymal giant cell astrocytoma (sega), 2.7 recommended dosage for tuberous sclerosis complex (tsc)-associated partial-onset seizures, 2.8 therapeutic drug monitoring (tdm) and dose titration for tuberous sclerosis complex (tsc)-associated subependymal giant cell astrocytoma (sega) and tsc-associated partial-onset seizures, 2.9 dosage modifications for adverse reactions, 2.10 dosage modifications for hepatic impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.